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Abstract 
Background. The vascular mortality of antiphospholipid syndrome (APS) ranges from 1.4% 
to 5.5% but its predictors are poorly known. Objectives. To evaluate the impact of baseline 
lupus anticoagulant assays, IgG anticardiolipin (aCL), plasma fibrinogen (FNG) and von 
Willebrand factor (VWF), platelets (PLT) and of genetic polymorphisms of 
methylenetetrahydrofolate reductase C677T, of prothrombin G20210A and of paraoxonase-1 
Q192R on mortality in primary APS (PAPS).  Patients. Cohort study on 77 thrombotic PAPS 
and 33 asymptomatic carriers of aPL (PCaPL) seen from 1989 to 2015 and persistently 
positive for aPL as per annual review. At baseline all participants were tested twice for the 
ratios of kaolin clotting time (KCTr), activated partial thromboplastin time (aPTTr), dilute 
Russell viper venom time (DRVVTr), IgG aCL, FNG, VWF and once for PLT. All thrombotic 
PAPS were on warfarin with regular INR monitoring. Results. During follow-up 11 PAPS 
deceased (D-PAPS) of recurrent thrombosis despite adequate anticoagulation yielding an 
overall vascular mortality of 10%. D-PAPS had the strongest baseline aPTTr and DRVVTr and 
the highest mean baseline IgG aCL, FNG, VWF and PLT. Cox proportional hazards model 
identified baseline DRVVTr and FNG as main predictors of mortality with adjusted hazard 
ratios of 5.75 (95%CI: 1.5, 22.4) and of 1.03 (95%CI: 1.01, 1.04) respectively. Conclusions. 
Plasma DRVVTr and FNG are strong predictors of vascular mortality in PAPS; while FNG 
lowering agents exist further research should be directed at therapeutic strategies able to 
dampen aPL production.  
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Introduction 
The primary antiphospholipid syndrome (PAPS) encompasses the occurrence of arterial and 
venous thrombosis in the presence and persistence of antiphospholipid antibodies (aPL) 
measured by immune and clotting assays and in the absence of any underlying autoimmune or 
chronic inflammatory disorder (1, 2). Unless adequately anticoagulated APS patients may 
undergo recurrent vascular occlusions but even when adequately anticoagulated some of them 
may suffer thrombotic recurrences that may be fatal (3, 4). In this respect a European 
multicentre survey has recently derived an all-cause mortality of 7.1% for PAPS but did not 
identify factors associated with mortality probably due to the multicentre nature that creates 
some difficulties when employing different reagents and methods across the participating 
centres (5). We have been following up patients with PAPS since 1989 and we evaluated the 
impact of several coagulation assays, haemostatic variables, thrombophilic and antioxidant 
genotypes on the mortality of this cohort.    
 
Patients and methods 
Patients  
This cohort includes 110 patients followed up since 1989 who were found positive for aPL on 
two separate occasions six weeks or three months apart according to evolving guidelines (1, 2). 
They were evaluated for a history of thrombosis and for a coagulation abnormality suggesting 
the presence of a lupus anticoagulant (LA). Since the inception of the cohort our focus was on 
vascular involvement (arterial and venous occlusions) hence women in whom aPL was sought 
as part of their obstetric assessment and women with miscarriages (with or without thrombosis) 
were not included and this reflects in our entry criteria. Inclusion criteria for this study were: 
regular follow-up for INR monitoring for thrombotic PAPS patients on oral anticoagulation 
and at least one yearly clinical and laboratory follow-up for persistent carriers of aPL (PCaPL) 
without underlying autoimmune or non-autoimmune diseases. Our exclusion criteria were: 1) 
history of miscarriages (with or without thrombosis) and/or positivity for aPL in women whose 
aPL was sought as part of their obstetric assessment, 2) any positive aPL in relation to 
autoimmune and/or inflammatory disorders, 3) APS related to systemic lupus erythematosus 
and secondary APS. The study was approved by the ethics committee of the Cardarelli 
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Hospital (Naples, Italy) and all participants gave written informed consent at the time of 
enrolment.  None of the authors declare any conflict of interest. 
Patients were followed up at the Haemostasis Unit of the Cardarelli Hospital in Naples 
(Italy) until its phased closure between June/October 2007 although the Haemostasis Unit had 
stopped seeing new patients by mid-2006. After June 2007 patients were followed-up under 
the umbrella of a patient association in a Clinical Pathology Laboratory (Multimedica, Naples, 
Italy), partially funded by the Regional Health Authority. During the observational period new 
patients accrued but those not having their INR monitored at our centre (n=16) and at least one 
annual follow-up (n=3) with the centre were not included in the current evaluation. The 
demographics of the cohort are depicted in Table 1.     
 
Blood sampling 
Blood samples for clotting assays were collected by venepuncture in 1/10 volume of 0.129 M 
trisodium citrate. After centrifuging at 2000 x g for 15 min at 4C, aliquots of platelet poor 
plasma (PPP) were stored at -70ºC for the measurement of fibrinogen (FNG) and von 
Willebrand factor (VWF) and the remaining were spun twice at 10.000 x g for 5 minutes to 
obtain platelet free plasma (PFP). Control platelet free plasma for clotting assays was obtained 
by 60 healthy hospital personnel (34F, 26M, mean age 33±19), aliquoted then frozen at -70ºC. 
Blood for serum preparation was collected into glass tubes, allowed to clot for 2 hours at room 
temperature, spun at 1000 x g for 10 minutes, aliquoted and frozen at -70ºC until use.  
 
Measurement of antiphospholipid antibodies 
PFP for LA assays were processed immediately; LA was detected by 1) activated partial 
thromboplastin time (aPTT) using rabbit brain kaolin (Diamed, Switzerland); 2) kaolin clotting 
time (KCT) according to the method of Exner (6); 3) dilute Russell’s viper venom time 
(DRVVT) according to the method of Thiagarajan (7). A clotting time ratio between patient 
and control sample greater than 1.2 for the aPTT, 1.18 for the DRVVT and 1.3 for the KCT 
indicated an abnormal result; the upper cut-offs for each assay was set at the 99th percentile 
from testing 60 plasmas from 38 females and 22 males who were healthy hospital personnel. In 
any of the assays, a clotting time of a 1:1 mixture of sample and pooled control plasma greater 
than that of pooled plasma alone suggested the presence of a lupus inhibitor. This was 
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confirmed by the platelet neutralisation procedure (PNP) according to Triplett (8), and by high 
phospholipid concentration according to Rosove (9). IgG and IgM anticardiolipin antibodies 
were measured by a commercially available ELISA (Melisa System, Cambridge Life Sciences, 
Ely, UK changed after June 2007 to Autozyme by the same company). A normal range was 
established using the same 60 healthy hospital personnel as mentioned above, with a cut-off of 
5GPL U/ml being 5 standard errors above the geometrical mean.  
During follow-up all patients of the cohort had their aPL status checked annually: those 
patients on warfarin whose LA was initially expressed in the aPTT (with or without DRVVT 
positivity) had its presence reconfirmed by comparing a sensitive and insensitive aPTT reagent 
to LA that allows the detection of LA whilst on warfarin (10); those patients whose LA was 
expressed only in the DRVVT had this rechecked after mixing with normal plasma if the INR 
was greater than 1.5 (reviewed in Moore (11).  
 
Measurement of plasma fibrinogen and von Willebrand factor 
Plasma concentrations of clottable FNG was measured in duplicate (Mascia Bruelli, Italy) 
according to Clauss (12); the coefficient of variation (CV) was 4.2%. Plasma VWF was 
measured in duplicate by Elisa (Boehringer Mannheim, Germany). Inter-and intrassay CV 
were 3.2% and 4.2% respectively.  Full blood counts were processed by an automated analyzer 
(Beckman Coulter, Italy).  All aPL and haemostatic variables assays were measured the first 
time between 3 and 6 months after the occlusive event to account for a possible transient acute 
phase reaction then re-tested the second time after six then twelve weeks according to 
guidelines (1, 2). None of the patients reported acute illnesses in the intervening period 
between aPL measurements. All data in the present study represent the mean of the values 
obtained on those two separate occasions but for the platelet count that was measured only 
once, at the time of the first aPL sampling.  
 
Determination of genetic thrombophilia 
The following gene polymorphisms were determined by polymerase chain reaction as 
described previously: C677T of the methylenetetrahydrofolate reductase (MTHFR), G20210A 
of prothrombin, A1691G of factor V Leiden (13) and Q192R of paraoxonase-1 (14).  
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Statistics 
Continuous variables are summarised by their mean, standard deviations, medians and 
interquartile ranges; transformation have been considered for non-symmetrical distributions. 
For the purpose of modelling time since diagnosis to death and for the calculation of the hazard 
ratio (HR) of death censoring time was considered from time of diagnosis to 26th May 2015. 
Appropriate statistical tests (parametric or non-parametric) have been implemented to compare 
crude differences between baseline variables across groups. Variables were log transformed 
when necessary to meet the assumptions required by the statistical models. 
The Cox Proportional Hazard (PH) model was applied to investigate the HR ratio of 
death since the baseline assessment in association with a series of demographic and clinical 
factors. This semi-parametric technique allows no assumption to be made on the baseline 
hazard though the proportionality of the hazards should hold. The latter assumption has been 
tested on the basis of Shoenfeld’s residuals after fitting the model to the data (15). Given the 
presence of missing data, multiple imputation techniques tailored to interval censored data 
have been implemented under missing at random assumption (16).  
 
Results 
Comparison of baseline variables across groups 
A comparison of baseline variables reveals that average IgG aCL (log transformed)(Figure 1A), 
DRVVTr (Figure 1D), platelet counts (Figure 1E), VWF Ag (Figure 1F) and FNG (Figure 1G) 
were highest in the D-PAPS than in the other groups.  
 
Follow-up of baseline variables 
During follow up none of the participants became fully negative to an aPL test but there were 
fluctuations and some negative tests became positive. Of 13 positive aPTT at baseline with a 
ratio between 1.2 and 1.5, 8 were still positive at last FUP; of 18 aPTT that were negative at 
baseline with a ratio <1.2, 4 had become positive with a ratio between 1.2-1.4. Of 17 positive 
DRVVT at baseline with a ratio between 1.19-1.30, 12 were still positive: 7 within the same 
baseline ratio, four with a ratio between 1.3-1.4, one with a ratio of 1.6. Of 16 negative 
DRVVT at baseline, 6 had become positive, 4 with a ratio between 1.18 and 1.3, one with a 
ratio of 1.42 and one with a ratio of 1.48). Of the 28 IgG aCL with a baseline value less than 
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20GPL, 12 were still negative under the same threshold, 4 became positive above 40 GPL rand 
the remainder fluctuated between 20-40 GPL. All other aPTT and DRVVT ratios as well as 
IgG aCL titres above those indicated remained positive at last follow up with variations that 
did not alter the aPL status of the individuals of the cohort.  
KCT 
 
Proportion of morbidity 
During follow-up 0.9% (1/110) of participants developed a hypernephroma that was resected 
without complications, 1.8% (2/110) developed a cerebral vasculopathy and 6.3% (7/110) 
developed essential hypertension; the latter two conditions were mutually exclusive and 
occurred all in the S-PAPS group and not in the D-PAPS group. With regards to non-fatal 
thrombotic recurrences 0.9% (1/110) patients developed bilateral adrenal infarction and 3.6% 
(4/110) recurrent deep vein thrombosis. These recurrences occurred despite patients being in 
the target range (INR 2.0-3.0); our time in target range was 80%; the INRs of these patients 
was upped by 0.5 INR units compared to the average of their INRs pre-recurrent event. With 
regards to bleeding episodes, 3.6% (4/110) participants suffered major bleeding episodes, all in 
the S-PAPS group: two metrorrhagias, one spontaneous and one due to fibroids (at an INR 3.2 
and 3.0 respectively); one gastrointestinal haemorrhage due to bleeding polyps (at an INR at 
3.2) in one male; one post traumatic subdural hematoma (at an INR 2.0–3.0) in a woman.   
 
Proportion of mortality 
The percentage of deaths of the whole cohort, including D-PAPS + surviving PAPS (S-PAPS) 
and PCaPL groups was 10% (11/110); by considering only the thrombotic groups (D-PAPS 
and S-PAPS) it was 11%. Most patients died of recurrent arterial occlusions: in this group one 
patient had nephrotic syndrome, one had slightly elevated cholesterol and two smoked (10 and 
15 cigarettes per day); the remaining deceased patients did not present other cardiovascular 
risk factors. Table 2 shows some laboratory and clinical features of the D-PAPS; the fatal 
recurrent events are split into unprovoked and provoked to highlight that the latter occurred in 
patients with medium titre IgG aCL and the lowest DRVVTr of this group.  
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Predictors of mortality by Cox proportional hazard  
Cox PH model explored the possible crude effect of demographic (age, gender), clinical (age at 
1st thrombosis, number of thrombosis), laboratory (baseline log IgG aCL, aPTTr, DRVVTr, 
KCTr, FNG, VWF, PLT) and genetic variables (MTHFR, PT, PON) on survival. Factor V 
Leiden was not included in the analysis as too few patients carried the mutation. Log IgG aCL, 
DRVVTr, FNG and PLT emerged as mortality predictors by univariate analysis. These factors 
underwent a multivariable analysis employing multiple chained imputation techniques that 
identified DRVVTr, FNG and PLT as independent predictors of mortality (Table 4). Figure 2 
also shows the effect of baseline DRVVTr, FNG and PLT on survival based on the adjusted 
multivariable model.  
 
Discussion 
The mortality of our cohort, all vascular related, was 10% (11% considering only the 
thrombotic patients) a figure almost 10 fold higher than the 1.4% vascular mortality derived 
from the PAPS group of the Euro-Phospholipid-Project (EPP)(5). Other surveys reported a 
vascular mortality of 5.5% in PAPS (17), and of 1.3% and 2.9% in a mix of secondary and 
primary APS (4, 18).  Other cohorts presented with a non-vascular mortality ranging from 
1.3% to 26.9% (4, 5, 17) but they included patients with systemic lupus erythematosus (SLE) 
and various autoimmune diseases (4, 5, 17) that were not present in our cohort hence none of 
our patients required immune suppression that could increase the risk of fatal infections (5, 17). 
Moreover all of our participants are from the same geographical area and on a Mediterranean 
diet that may account for a higher intake of anti-oxidants and a lesser intake of carcinogens: 
this may explain the lack of cancer related mortality and the low prevalence of cardiovascular 
traditional risk factors in the patients deceased for arterial occlusions (19, 20).  
The previous studies did not evaluate predictors of mortality though it was known that 
APS adversely affected survival of patients with SLE (21). We had the opportunity to 
investigate predictors of mortality across three groups of patient: D-PAPS, S-PAPS and PCaPL, 
the latter a group of persistent carriers of aPL who never suffered thrombosis throughout the 
follow-up: amongst aPL tests at baseline our D-PAPS patients showed the highest average IgG 
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aCL titres and the strongest average DRVVTr whereas amongst baseline haemostatic variables 
our D-PAPS presented with the highest average FNG, PLT and VWF levels. 
The baseline impact of aPL tests, haemostatic variables and some clinical and genetic 
factors on survival was approached by the Cox PH model: baseline DRVVTr independently 
and adversely affected survival with a HR of almost 6, that is, for each unit increase in 
DRVVTr the risk of death increased almost six times and the same applied for plasma FNG 
and PLT counts but with lower HRs. Amongst our D-PAPS, those with the highest DRVVTr 
all passed away for recurrent spontaneous thrombosis, whereas two passed away for provoked 
events (post-partum and post heart valve surgery) that may have contributed to catastrophic 
APS despite having IgG aCL titres and DRVVT ratios amongst the lowest of the group. We 
had previously demonstrated that DRVVT was the only LA assay that correlated with a history 
of arterial occlusions, prior to the diagnosis of PAPS (22),  but this is the first report of a 
graded adverse effect for the DRVVT, where the stronger its ratio, the worse the survival.  A 
Finnish survey found that LA detected by a re-calcification time (23) and by KCT (6) was 
related to vascular mortality in a small cohort of SLE patients: the mortality was explained in 
categorical fashion on the basis of the presence or absence of the LA (24). A decade later the 
LA resulted as an independent predictor of venous thromboembolism but not of mortality in a 
much larger cohort of SLE patient but the authors did not mention which LA assay was 
employed (25). Despite the obvious poor comparability, the predictive pattern of our aPL panel 
is similar to that of a study on obstetric APS, where the LA was superior to aCL and a2GPI of 
either IgM/IgG isotype in predicting adverse pregnancy outcome, though DRVVT and aPTT 
were equally predictive (26). Very recently an Austrian group sought predictors of mortality in 
a cohort of 151 participants positive for LA detected as aPTT and DRVVT followed up for a 
median of just over 8 years: after adjustment for age and hypertension they identified 
occurrence of new thrombosis as the strongest predictor of mortality but not LA (27).  
The role of other haemostatic markers as possible predictors of survival has never been 
explored in APS; with regards to plasma FNG we had described its association with a history 
of arterial thrombosis (22) and its relation to the intima media thickness of carotid arteries (in 
univariate analysis) in patients from this same cohort (28). A meta-analysis from 1999, 
including thirteen prospective studies, estimated that apparently healthy subjects in the higher 
baseline tertile of plasma FNG had twice the odds of developing cardiovascular disease over 
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time than subjects in the lower baseline tertile (29). Moreover, elevated FNG emerged as an 
independent predictor of mortality not only in patients with a previous stroke with a HR of 
1.71 (30) but also in normal subjects with an adjusted HR of 1.05 (31). Similar data derived 
from the Thrombosis Prevention Trial showed that FNG conferred a HR of 1.59 for fatal 
coronary heart disease and 1.56 for fatal ischaemic stroke (32). The predictive value of 
elevated PLT counts on short and medium term all-cause mortality has been established in the 
general elderly population (33), in chronic obstructive pulmonary disease (34) as well as in 
solid tumours (35). A relationship between thrombocytosis and vascular mortality in APS has 
never been noted before.  
Amongst our demographic and clinical factors, age, sex, age at 1st event and number of 
thrombosis were not associated with mortality, contrary to other reports (27); we also explored 
the possible contribution of MTHFR and PON genotypes. With regards to the homozygous 
MTHFR mutation we had shown that homozygous MTHFR PAPS patients suffered their first 
thrombotic event at an earlier age compared to heterozygous and homozygous normal PAPS 
patients (36). With regards to PON we had noted that antibodies against high density 
lipoprotein (HDL) were inhibitory against PON activity favouring oxidative stress (37). 
Because anti-HDL was not measured at baseline in this cohort we considered PON genotypes 
instead, determined on 75 participants only, as homozygous and heterozygous PON mutations 
code for enzymes with reduced antioxidant activity that favour oxidative stress: the latter 
occurs in PAPS (38) and is involved in platelet activation and atherosclerosis (39). Neither 
homozygous MTHFR nor PON mutations had any impact on survival even if the combined 
frequency of homozygous and heterozygous PON mutations was more common in D-PAPS.   
Our studies has several limitations: 1) although FNG and VWF were measured between 
three to six months after the vascular occlusion, we did not check C-reactive protein to exclude 
the possibility of a persisting low grade acute phase reaction, though we minimized this 
possibility by averaging the measurement of plasma FNG and VWF at the time the two aPL 
tests were checked; 3) the PLT counts was measured only once at the time of the first aPL 
check and we did not pursue any genetic test to ascertain the possibility of a myeloproliferative 
disorder during follow-up as only three patients had a PLT count above 4x199/L. We 
retrospectively checked the Jak2 mutation on a frozen DNA sample from the patient who 
passed away for Budd-Chiari syndrome and it yielded a homozygous normal result; 4) we did 
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not evaluate the predictive role of a2GPI either on its own or as part of the triple positivity 
concept (40) because we did not have frozen baseline aliquots available for all patients; 5) we 
did not include data on smoking status because we had cross-sectional information only for 
50% of the cohort and we argued that recall based on a questionnaire would not effectively 
capture the annual average consumption.    
Notwithstanding, we report a 10% vascular mortality for our PAPS cohort that 
excluded obstetric, secondary of systemic lupus associated APS; more importantly amongst the 
baseline variables we highlighted for the first time the independent predictive role of DRVVT 
and FNG on mortality. Moreover, warfarin was unable to prevent spontaneous ischaemic 
stroke in 66% (6/9) and myocardial infarction in 11% (1/9) of the D-PAPS group, challenging 
the preventative efficacy of antivitamin K anticoagulants against recurrent arterial occlusion in 
PAPS. Likewise unfractionated heparin was ineffective in preventing the death of the two 
patients whose fatal events were provoked. Targeting modifiable risk factors such as sedentary 
behaviour, diet, smoking, homocysteine and plasma FNG are intuitive strategies to reduce the 
vascular risk of PAPS but therapeutic measures to dampen the production of aPL are urgently 
required.  
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Table 1. Demographics of the cohort 
 
 
 
 
 
 
 
 
 
 
 
 PcaPL S-PAPS D-PAPS 
No 33 66 11 
M/F 5/26 23/43 5/6 
Age  48.5±15.8 47.3±14.3 55.5±8.9 
Age 1st event  Na 33.9±12.5 40.1±16.3 
Time 1st event to PAPS 
diagnosis, years 
 1.08±0.38 1.09±0.33 
 
FUP, years 12±3.7 10.3±3.7 7.9±2.7 
    
Total thrombosis Na 66 11 
 No % No % No % 
No 1   44 66.6 4 36.3 
No 2   15 22.8 4 36.3 
No 3   7 10.6 1 9.1 
No 4   0 0 2 18.1 
       
Thrombosis  type       
Arterial   20 30.3 6 54.5 
Venous   45 68.1 5 45.5 
Arterial + venous   1 1.5 0  
       
IgG aCL  <20   (GPL) 15 45 13 20 0 0 
IgG aCL 21-40 (GPL) 7 21 15 22 2 18 
IgG aCL 41-80 (GPL) 4 12 10 15 2 18 
IgG aCL >80    (GPL) 7 22 28 28 7 64 
       
FVL +/- 0 0 2 3 0 0 
PT +/- 2 6 5 7.5 0 0 
MTHFR +/+ 8 24.2 14 21.2 2 18.1 
PON +/+ 2 6 4 6.2* 2 18.1 
PON +/- 17 51.5 17 26.7* 5 45.4 
PON +/+ & +/- 19 57.5 21 32.8* 7 63.6# 
    
Antithrombotic agents    
Warfarin 0 0 66 100 11 100 
Aspirin  4 12 0 0 1 9 
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Table 2. Laboratory and clinical features of deceased primary antiphospholipid patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 INR IgG aCL DRVVTr 1st event Fatal event 
Age/Sex Pre-event At event Baseline Year of  fatality Baseline Year of fatality   Unprovoked 
52/F 3.6 3.8 999 1180 3.05 3.34 IS IS 
57/M 2.8 2.4 1000 858 3.00 2.88 IS, AI IS, necrotic toes 
41/M 2.5 2.7 400 540 2.62 2.79 DVT Saddle PE +PTA 
59/M 2.4 2.7 380 359 2.58 3.02 IS IS● 
49/M 3.3 3.9 321 353 2.52 2.84 RAT IS 
45/F 2.7 2.9 160 188 2.20 2.33 RVT* MI 
55/M 2.8 2.5 130 101 2.11 2.23 DVT IS 
47/F 2.7 na# 55 68 1.74 1.92 DVT BCS 
50/F 2.6 2.9 34 52 1.53 1.68 DVT DVT + IS● 
       Provoked 
50/F 2.7 UFH 60 75 1.77 1.58 IS MI/IS post AVR@ 
38/F 2.6 UFH 37 55 1.43 1.55 DVT CAPS post-partum 
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Table 3. Univariate survival analysis  
 
Variable HR p-value 95%CI Observations 
   Low  High No 
Age 1.030 0.10 0.993 1.069 110 
Gender 2.104 0.22 0.641 6.904 110 
Age 1st event 1.031 0.16 0.987 1.076 77 
Event No 2 2.442 0.20 0.609 9.793 77 
Event No 3 4.173 0.06 0.932 18.687 77 
      
Log IgG aCL 8.288 0.001 2.362 29.073 110 
KCTr 0.754 0.47 0.348 1.633 110 
APTTr 1.502 0.23 0.766 2.945 110 
DRVVTr 8.582 <0.0001 3.789 19.438 110 
PLT 1.015 <0.0001 1.007 1.022 94 
VWF Ag 1.011 0.21 0.993 1.030 96 
FNG 1.027 <0.0001 1.016 1.038 100 
      
PT +/- 1.326 0.78 0.169 10.366 109 
MTHFR +/- 1.278 0.71 0.342 4.764 109 
MTHFR +/+ 0.833 0.83 0.152 4.558 109 
PON +/- 1.919 0.33 0.514 7.158 75 
PON +/+ 4.001 0.11 0.731 21.889 75 
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Table 4. Multivariable survival analysis: Cox proportional hazard most  
parsimonious model 
Adjusted multiple imputation 
parameter estimates 
  95%CI 
HR p-value Low High 
DRVVTr 5.751 0.012 1.472 22.459 
FNG  1.029 <0.0001 1.014 1.044 
PLT 1.017 0.003 1.006 1.026 
 
